Table 1. Drug sensitivity of Ewing's sarcoma cell lines to mouse anti-DR4 and DR5, Conatumumab (CONA), and CONA+anti-Fc.
|
DR4 mouse Mab |
DR5 mouse Mab |
CONA |
CONA+Anti-Fc |
|||||
|---|---|---|---|---|---|---|---|---|
| Agent | IC50 (ng ml−1) | Viability (%) at 1 μg ml−1 | IC50 (ng ml−1) | Viability (%) at 1 μg ml−1 | IC50 (ng ml−1) | Viability (%) at 1 μg ml−1 | IC50 (ng ml−1) | Viability (%) at 1 μg ml−1 |
| RH1 | >1000 | 99.6 | 9.3 | 2.1 | >1000 | 81.1 | 2.3 | 5.1 |
| TC71 | 88.1 | 25.1 | 47.5 | 3.5 | >1000 | 90.2 | 5.1 | 7.9 |
| RD-ES | 13.2 | 15.5 | 11.1 | 3.0 | >1000 | 91.2 | 1.8 | 4.0 |
| SKN-MC | >1000 | 102.0 | 28.9 | 10.6 | >1000 | 93.1 | 2.5 | 8.4 |
| TC106 | >1000 | 66.1 | 10.1 | 33.1 | >1000 | 91.6 | 30.0 | 42.2 |
| TC32 | >1000 | 82.7 | 12.6 | 33.4 | >1000 | 100.0 | 3.8 | 9.8 |
| KAD | >1000 | 97.7 | 98.9 | 18.9 | >1000 | 94.9 | 3.9 | 15.9 |
| A4573 | >1000 | 97.1 | >1000 | 99.9 | >1000 | 95.3 | >1000 | 92.3 |
| A673 | >1000 | 54.0 | 9.2 | 7.2 | >1000 | 70.0 | 3.1 | 7.2 |
| VW | >1000 | 88.3 | 7.0 | 18.4 | >1000 | 68.3 | 3,3 | 18.1 |
| LD | >1000 | 92.1 | >1000 | 78.1 | >1000 | 96.7 | 700.9 | 42.8 |
| 5838 | >1000 | 90.1 | 29.2 | 5.2 | >1000 | 100.0 | 3.9 | 7.9 |
| MDA231 | 27.7 | 44.6 | 30.9 | 25.6 | >1000 | 95.9 | 3.0 | 11.6 |
| SkMDC | >1000 | 100 | >1000 | 97 | >1000 | 100 | >1000 | 95 |
Abbreviations: DR=death receptor; IC50=half maximal inhibitory concentration; Mab=monoclonal antibody. The percent viability was defined as the ratio between viable cells at the indicated drug dose and that of the no-drug control. MB-231, positive control breast cancer cell line; SkMDC, TRAIL-resistant primary human skeletal muscle-derived cells.